Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 5/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NCK1 | P16333 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA9 | Q16790 | 3/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL27919193 | 0.97 | CYP2A6 (0.65) | CYP2A6CYP1A2TDP1CYP3A4ALDH1A1 | |
| SCHEMBL3840695 | 0.92 | CYP2A6 (0.70) | CYP2A6CYP1A2TDP1CYP3A4ALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27919192 | 0.90 | CYP2A6 (0.67) | CYP2A6CYP1A2TDP1CYP3A4ALDH1A1 | |
| SCHEMBL2723074 | 0.88 | CYP2A6 (0.52) | CYP2A6CYP1A2TDP1CYP3A4ALDH1A1 | |
| SCHEMBL29644361 | 0.83 | CYP2A6 (0.77) | CYP2A6TDP1CYP3A4ALDH1A1LMNA | |
| SCHEMBL29389285 | 0.83 | CYP1A2 (1.00) | CYP2A6CYP1A2TDP1CYP3A4ALDH1A1 | |
| SCHEMBL308248 | 0.83 | CYP1A2 (1.00) | CYP2A6CYP1A2TDP1CYP3A4ALDH1A1 | |
| SCHEMBL865990 | 0.83 | CYP2A6 (0.77) | CYP2A6TDP1CYP3A4ALDH1A1LMNA | |
| SCHEMBL10882769 | 0.80 | CYP1A2 (0.93) | CYP2A6CYP1A2TDP1CYP3A4ALDH1A1 | |
| SCHEMBL10882775 | 0.80 | CYP1A2 (0.93) | CYP2A6CYP1A2TDP1CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228472-A1 | HETEROCYCLIC COMPOUND AND HARMFUL-ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228472-A1 | HETEROCYCLIC COMPOUND AND HARMFUL-ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20230133581-A1 | Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same | HIROSHIMA UNIVERSITY (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230133581-A1 | Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same | HIROSHIMA UNIVERSITY (JP) | 2023-05-04 | — | — | US | disclosed |
| US-20230047589-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ALTOS LABS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230042881-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2023-02-09 | — | — | US | disclosed |
| WO-2023284860-A1 | 3-PHENYLPROPIONIC ACID COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL APPLICATION THEREOF | 江苏恒瑞医药股份有限公司 | 2023-01-19 | — | — | WO | disclosed |
| EP-4119165-A1 | NOVEL 3,5-DIAMINOBENZOIC ACID COMPOUND, AND PIN1 INHIBITOR AND THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES USING SAME | Hiroshima University (JP) | 2023-01-18 | — | — | EP | disclosed |
| US-11318133-B2 | Modulators of integrated stress response pathway | Praxis Biotech LLC (US) | 2022-05-03 | — | — | US | disclosed |
| WO-2000032590-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999037304-A1 | SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-07-29 | — | — | WO | disclosed |
| EP-0115679-B1 | CHEMICAL PROCESS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-10-14 | — | — | EP | disclosed |
| US-4611062-A | Process for resolving certain spiro compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-09-09 | — | — | US | disclosed |
| US-4567278-A | Process for racemizing certain spiro compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-28 | — | — | US | disclosed |
| US-4523021-A | ANTIDIABETIC AND ANTIGLACTOSEMIA AGENT | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-06-11 | — | — | US | disclosed |
| EP-0065407-B1 | PHARMACEUTICAL SPIRO-SUCCINIMIDE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-03-13 | — | — | EP | disclosed |
| US-4478847-A | ALDOSE REDUCTASE INHIBITORS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-10-23 | — | — | US | disclosed |
| EP-0115679-A1 | Chemical process | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-08-15 | — | — | EP | disclosed |
| EP-0065407-A2 | Pharmaceutical spiro-succinimide derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-11-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230042881-A1 | MODULATORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, ATF1, DDIT3 | CYP2A6 4132/4885CYP1A2 4650/4885TDP1 1502/4885 |
| US-20230133581-A1 | Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same | PIN1, DUSP15, FKBP1A | CYP2A6 617/4885CYP1A2 1141/4885TDP1 3878/4885 |
| US-20240228472-A1 | HETEROCYCLIC COMPOUND AND HARMFUL-ARTHROPOD-CONTROLLING COMPOSITION CONTAINING SAME | CYC1, CRY1, C1S | CYP2A6 177/4885CYP1A2 45/4885TDP1 3909/4885 |
| US-11318133-B2 | Modulators of integrated stress response pathway | ATF4, ATF1, DDIT3 | CYP2A6 4132/4885CYP1A2 4650/4885TDP1 1502/4885 |
| US-20230047589-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | CYP2A6 4003/4885CYP1A2 4440/4885TDP1 1045/4885 |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | PIN1, ACE2, ACE | CYP2A6 3671/4885CYP1A2 4049/4885TDP1 3987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.